Clinical translation of advanced colonic drug delivery technologies

Archive ouverte

Awad, Atheer | Madla, Christine M. | Mccoubrey, Laura E. | Ferraro, Fabiana | Gavins, Francesca K. H. | Buanz, Asma | Gaisford, Simon | Orlu, Mine | Siepmann, Florence | Siepmann, Juergen | Basit, Abdul W.

Edité par CCSD -

International audience. Targeted drug delivery to the colon offers a myriad of benefits, including treatment of local diseases, direct access to unique therapeutic targets and the potential for increasing systemic drug bioavailability and efficacy. Although a range of traditional colonic delivery technologies are available, these systems exhibit inconsistent drug release due to physiological variability between and within individuals, which may be further exacerbated by underlying disease states. In recent years, significant translational and commercial advances have been made with the introduction of new technologies that incorporate independent multi-stimuli release mechanisms (pH and/or microbiota-dependent release). Harnessing these advanced technologies offers new possibilities for drug delivery via the colon, including the delivery of biopharmaceuticals, vaccines, nutrients, and microbiome therapeutics for the treatment of both local and systemic diseases. This review details the latest advances in colonic drug delivery, with an emphasis on emerging therapeutic opportunities and clinical technology translation.

Consulter en ligne

Suggestions

Du même auteur

Machine learning of Raman spectra predicts drug release from polysaccharide coatings for targeted colonic delivery

Archive ouverte | Abdalla, Youssef | CCSD

International audience. Colonic drug delivery offers numerous pharmaceutical opportunities, including direct access to local therapeutic targets and drug bioavailability benefits arising from the colonic epithelium'...

Colon targeting in rats, dogs and IBD patients with species-independent film coatings

Archive ouverte | Ferraro, Fabiana | CCSD

International audience. Polysaccharides were identified, which allow for colon targeting in human Inflammatory Bowel Disease (IBD) patients, as well as in rats and dogs (which are frequently used as animals in precl...

Poly(D,l-lactide-co-glycolide) particles are metabolised by the gut microbiome and elevate short chain fatty acids.

Archive ouverte | Mccoubrey, L. E. | CCSD

International audience. The production of short chain fatty acids (SCFAs) by the colonic microbiome has numerous benefits for human health, including maintenance of epithelial barrier function, suppression of coliti...

Chargement des enrichissements...